MedTrace Logo

Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

NCT01266174 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2015-04-14

No results posted yet for this study

Summary

The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.

Conditions

Interventions

DRUG

Eltoprazine

Comparison of eltoprazine, dosed orally, for 8 weeks

DRUG

Placebo

Placebo to match eltoprazine

Sponsors & Collaborators

  • Amarantus BioScience Holdings, Inc.

    lead INDUSTRY

Principal Investigators

  • John G Csernansky, MD · NortWestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-09-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01266174 on ClinicalTrials.gov